CognitiveResearch Phase

Galanin

Investigational

Overview

Galanin is a 29 or 30 amino acid neuropeptide widely distributed throughout the central and peripheral nervous systems. It acts through three G protein-coupled receptor subtypes (GAL1, GAL2, and GAL3) to modulate neurotransmission, particularly in cholinergic, serotonergic, and noradrenergic pathways.

Mechanism of Action

The peptide has been implicated in cognitive processes, mood regulation, feeding behavior, and neuroprotection, making it a target of interest for neurodegenerative and psychiatric conditions..

Research Summary & Key Findings

Preclinical studies in rodent models have demonstrated that galanin modulates hippocampal acetylcholine release and affects performance in spatial learning tasks. Elevated galanin expression has been observed in postmortem brain tissue from patients with Alzheimer's disease, though the functional significance remains under investigation. No galanin-based therapeutics have advanced to late-stage clinical trials in cognitive disorders to date.

Clinical Status

Research Phase

Galanin is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Investigational

Related Peptides in Cognitive

Find a Provider

Find a verified provider who offers Galanin therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Galanin.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.